SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77269.40
355.9 (0.46%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,33,848 Large Cap	1,824.10 (0.88%)	39.75	5.34	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Divis Laboratories Ltd.	Q V+ PT	1,72,697 Large Cap	6,618.20 (1.73%)	69.66	10.8	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,41,859 Large Cap	4,252.05 (1.44%)	62.44	15.62	7.72	15.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Dr. Reddys Laboratories Ltd.	Q V PT	1,10,421 Mid Cap	1,287.95 (-2.65%)	19.83	2.97	13.26	22.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,09,840 Large Cap	7,738.05 (1.29%)	76.08	11.33	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Cipla Ltd.	Q V PT	1,05,811 Large Cap	1,334.85 (1.90%)	23.27	3.15	9.97	30.14	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Lupin Ltd.	Q V PT	1,05,320 Mid Cap	2,350.95 (2.05%)	22.67	5.06	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Max Healthcare Institute Ltd.	Q V PT	96,663 Mid Cap	1,011.45 (1.84%)	68.11	9.33	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Mankind Pharma Ltd.	Q V PT	92,744 Mid Cap	2,260.60 (0.63%)	54.44	5.81	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Zydus Lifesciences Ltd.	Q V PT	89,721 Mid Cap	901.65 (1.12%)	18.17	3.42	10.27	30.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Aurobindo Pharma Ltd.	Q V+ PT	80,705 Mid Cap	1,375.80 (-0.99%)	37.88	3.66	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Fortis Healthcare Ltd.	Q V+ PT	69,709 Mid Cap	952.75 (3.18%)	427.3	7.57	15.55	-22.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Glenmark Pharmaceuticals Ltd.	Q V+ PT	67,885 Mid Cap	2,392.60 (-0.54%)	63.74	6.8	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Alkem Laboratories Ltd.	Q V PT	64,614 Mid Cap	5,355.20 (-0.90%)	29.45	4.52	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Laurus Labs Ltd.	Q V+ PT	59,336 Mid Cap	1,166.50 (6.13%)	66.76	11.2	14.42	4.11	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Biocon Ltd.	Q V PT	58,280 Mid Cap	360.40 (0.24%)	7875.64	2.16	2.44	-9.71	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Abbott India Ltd.	Q V PT	54,039 Mid Cap	25,426.70 (-0.02%)	35.46	12.32	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Anthem Biosciences Ltd.	Q V PT	42,676 Mid Cap	764.10 (0.57%)	84.31	14.39	23.81	40.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	39,566 Mid Cap	2,351.10 (0.66%)	38.75	19.75	3.06	33.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Ipca Laboratories Ltd.	Q V+ PT	38,847 Mid Cap	1,530.60 (-0.04%)	48.25	5.04	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Aster DM Healthcare Ltd.	Q V+ PT	36,341 Small Cap	744.70 (6.17%)	93.63	7.94	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Narayana Hrudayalaya Ltd.	Q V PT	36,093 Mid Cap	1,792.10 (1.47%)	46.34	8.61	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Ajanta Pharma Ltd.	Q V PT	35,289 Small Cap	2,904.15 (2.82%)	34.78	7.69	12.43	17.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	32,884 Small Cap	2,078.55 (1.49%)	45.21	8.43	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Emcure Pharmaceuticals Ltd.	Q V PT	31,850 Small Cap	1,785.15 (6.26%)	49.86	9.17	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Global Health Ltd.	Q V PT	30,048 Small Cap	1,171 (4.77%)	64.55	7.74	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Gland Pharma Ltd.	Q V PT	28,849 Small Cap	1,817.30 (3.79%)	24.68	2.79	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Krishna Institute of Medical Sciences Ltd	Q V PT	26,651 Small Cap	682.45 (2.46%)	92.44	11.28	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Dr. Lal Pathlabs Ltd.	Q V PT	22,935 Small Cap	1,573.45 (15.01%)	45.13	9.27	13.05	17.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Sai Life Sciences Ltd.	Q V+ PT	22,695 Small Cap	1,082.70 (1.15%)	69.01	9.45	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Dr. Lal Pathlabs	1,573.45	15.01%
Innova Captab	845.90	12.62%
Aarti Pharmalabs	805.70	8.26%
Neuland Laboratories	16,135.75	7.58%
Blue Jet Healthcare	476.35	7.39%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Shree Ganesh Remed.	487.20	-5.33%
Fermenta Biotech	299.35	-3.87%
Anuh Pharma	79.70	-2.79%
Cohance Lifesciences	469.95	-2.69%
Dr. Reddys Lab	1,287.95	-2.65%

News about Top Pharma Companies in India

May, 2026

Zydus Lifesciences shines as its arm acquires 100% stake in FBC Medical

The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents

May, 2026

Dr. Lal PathLabs informs about update on acquisition

In continuation to its earlier intimation dated April 30, 2026 with respect to acquisition of 100% stake in Shahbazkers Diagnostic Centre (‘SDCPL’) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Dr. Lal PathLabs has informed that the Company has completed the said acquisition on May 01, 2026 as per the terms and conditions of the Share Purchase Agreement. Pursuant to completion of said acquisition, SDCPL has now become Wholly Owned Subsidiary of the Company. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time, have already been duly intimated in the earlier intimation dated April 30, 2026.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Max Healthcare Institute informs about allotment of equity shares

Max Healthcare Institute has informed that Nomination & Remuneration Committee (‘NRC’) of the Company on May 1, 2026, at 6.56 pm (IST), has approved the allotment of 51,287 equity shares having face value of ?10 each, fully paid-up, to eligible employees, consequent to the exercise of vested stock options in accordance with Max Healthcare Institute Limited - Employee Stock Option Scheme 2022. Consequent to the above allotment, the paid-up equity share capital of the Company stands increased from 973,19,25,020 to 973,24,37,890. In terms of regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the requisite details of equity shares allotted as above are enclosed as Annexure. This disclosure will also be hosted on Company's website: www.maxhealthcare.in.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Laurus Labs informs about press release

Laurus Labs has informed that it enclosed copies of the newspaper advertisement pertaining to Financial Results of the Company for the quarter and year ended March 31, 2026. The advertisements were published in Business Standard (English) and Prajasakti (Telugu) on May 01, 2026.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Aster DM Healthcare informs about earnings call

Aster DM Healthcare has informed that the Earnings Call of the Company for the quarter and year ended March 31, 2026, was held on May 01, 2026, and the Video/Audio Recording with respect to Earnings Call is available on the website of the Company at https://www.asterdmhealthcare.in/investors/financial-information/audio-video-recordings-earningsquarterly-calls.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Zydus Lifesciences’ arm acquires 100% stake in FBC Medical

The acquisition is intended to internalize commercial capabilities currently outsourced to third-party sales agents

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,33,848 Crore
2	Divis Laboratories Ltd.	1,72,697 Crore
3	Torrent Pharmaceuticals Ltd.	1,41,859 Crore
4	Dr. Reddys Laboratories Ltd.	1,10,421 Crore
5	Apollo Hospitals Enterprise Ltd.	1,09,840 Crore
6	Cipla Ltd.	1,05,811 Crore
7	Lupin Ltd.	1,05,320 Crore
8	Max Healthcare Institute Ltd.	96,663 Crore
9	Mankind Pharma Ltd.	92,744 Crore
10	Zydus Lifesciences Ltd.	89,721 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,427	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,252	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,904	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,351	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	902	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,079	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,261	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,167	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,288	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,904	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	902	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,335	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,824	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,288	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,079	32,884	45.21	8.43	28.55	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Zydus Lifesciences shines as its arm acquires 100% stake in FBC Medical

Dr. Lal PathLabs informs about update on acquisition

Max Healthcare Institute informs about allotment of equity shares

Laurus Labs informs about press release

Aster DM Healthcare informs about earnings call

Zydus Lifesciences’ arm acquires 100% stake in FBC Medical

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.